A Phase I Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Doses of RG7667 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs RG 7667 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions
- Sponsors Genentech
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Jun 2012 Planned end date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.